Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56


M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.

Lockmer S, Ren W, Brodtkorb M, Østenstad B, Wahlin BE, Pan-Hammarström Q, Kimby E.

Br J Haematol. 2019 Aug 18. doi: 10.1111/bjh.16159. [Epub ahead of print]


Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.

Zucca E, Rondeau S, Vanazzi A, Østenstad B, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, de Nully Brown P, Hagberg H, Ferreri AJM, Lohri A, Novak U, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei SB, Ghielmini M, Kimby E; Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group.

Blood. 2019 Jul 25;134(4):353-362. doi: 10.1182/blood-2018-10-879643. Epub 2019 May 17.


A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.

Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, Østenstad B, Liestøl K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingjærde OC, Brodtkorb M.

Haematologica. 2019 Mar 7. pii: haematol.2018.209080. doi: 10.3324/haematol.2018.209080. [Epub ahead of print]


Reply to M. Sorigue et al.

Lockmer S, Østenstad B, Hagberg H, Holte H, Wahlin BE, Wader KF, Smedby KE, Brown P, Kimby E.

J Clin Oncol. 2019 Mar 20;37(9):759-760. doi: 10.1200/JCO.18.02362. Epub 2019 Feb 8. No abstract available.


TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.

Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH.

Cancer Immunol Res. 2019 Mar;7(3):355-362. doi: 10.1158/2326-6066.CIR-18-0351. Epub 2019 Jan 18.


Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.

Lockmer S, Østenstad B, Hagberg H, Holte H, Johansson AS, Wahlin BE, Wader KF, Steen CB, Meyer P, Maisenhølder M, Smedby KE, Brown P, Kimby E.

J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262. [Epub ahead of print]


T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH.

Clin Cancer Res. 2018 Feb 15;24(4):870-881. doi: 10.1158/1078-0432.CCR-17-2337. Epub 2017 Dec 7.


The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.

Blaker YN, Spetalen S, Brodtkorb M, Lingjaerde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB.

Br J Haematol. 2016 Oct;175(1):102-14. doi: 10.1111/bjh.14201. Epub 2016 Jun 24.


A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, Holte H.

Br J Haematol. 2016 May;173(3):432-43. doi: 10.1111/bjh.13965. Epub 2016 Feb 23.


Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.

Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE.

Mol Oncol. 2015 Oct;9(8):1553-64. doi: 10.1016/j.molonc.2015.04.008. Epub 2015 May 8.


Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas.

Kimby E, Östenstad B, Brown P, Hagberg H, Erlanson M, Holte H, Linden O, Johansson AS, Ahlgren T, Wader K, Wahlin BE, Delabie J, Sundström C; Nordic Lymphoma Group (NLG).

Leuk Lymphoma. 2015;56(9):2598-607. doi: 10.3109/10428194.2015.1014363. Epub 2015 Mar 11.


Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group.

Pulczynski EJ, Kuittinen O, Erlanson M, Hagberg H, Fosså A, Eriksson M, Nordstrøm M, Østenstad B, Fluge Ø, Leppä S, Fiirgaard B, Bersvendsen H, Fagerli UM.

Haematologica. 2015 Apr;100(4):534-40. doi: 10.3324/haematol.2014.108472. Epub 2014 Dec 5.


High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008.

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, Holte H.

Tidsskr Nor Laegeforen. 2013 Sep 3;133(16):1704-9. doi: 10.4045/tidsskr.13.0243. English, Norwegian.


Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy.

Wahlin BE, Sundström C, Sander B, Christensson B, Jeppsson-Ahlberg Å, Hjalmarsson E, Holte H, Østenstad B, Brown PD, Smeland EB, Kimby E.

Leuk Lymphoma. 2014 Feb;55(2):288-95. doi: 10.3109/10428194.2013.802778. Epub 2013 Jun 14.


Evidence for long-term hypercoagulopathy, but normalization of markers of extracellular matrix turnover, in patients with non-Hodgkin lymphoma.

Iversen PO, Negaard H, Østenstad B, Sandset PM, Kolset SO.

Leuk Lymphoma. 2015;56(8):2479-81. doi: 10.3109/10428194.2013.803227. Epub 2013 Jun 12. No abstract available.


Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.

Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M.

Ann Oncol. 2013 May;24(5):1385-92. doi: 10.1093/annonc/mds621. Epub 2012 Dec 17.


Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.

Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume B.

Breast Cancer Res. 2012 Aug 14;14(4):R117. doi: 10.1186/bcr3242.


Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.

d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE.

J Clin Oncol. 2012 Sep 1;30(25):3093-9. doi: 10.1200/JCO.2011.40.2719. Epub 2012 Jul 30.


Entourage: the immune microenvironment following follicular lymphoma.

Wahlin BE, Sander B, Christensson B, Ostenstad B, Holte H, Brown PD, Sundström C, Kimby E.

Blood Cancer J. 2012 Jan;2(1):e52. doi: 10.1038/bcj.2011.53. Epub 2012 Jan 20.


Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.

Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE.

Breast Cancer Res. 2012 Mar 15;14(2):R47.


Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment.

Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordøy T, Dudman S, Kilander A, Wader KF, Ostenstad B, Ekanger R, Meyer P, Kolstad A.

Blood. 2011 Dec 22;118(26):6769-71. doi: 10.1182/blood-2011-08-372649. Epub 2011 Nov 4.


Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE.

PLoS One. 2011 Apr 27;6(4):e19249. doi: 10.1371/journal.pone.0019249.


T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab.

Wahlin BE, Sundström C, Holte H, Hagberg H, Erlanson M, Nilsson-Ehle H, Lindén O, Nordström M, Ostenstad B, Geisler CH, Brown Pde N, Lehtinen T, Maisenhölder M, Tierens AM, Sander B, Christensson B, Kimby E.

Clin Cancer Res. 2011 Jun 15;17(12):4136-44. doi: 10.1158/1078-0432.CCR-11-0264. Epub 2011 Apr 25.


Associations between regulators of extracellular matrix and hemostatic factors in hematologic neoplasias.

Negaard HF, Sandset PM, Kolset SO, Svennevig K, Østenstad B, Iversen PO.

Leuk Lymphoma. 2011 Jun;52(6):1157-9. doi: 10.3109/10428194.2011.563886. Epub 2011 Apr 4. No abstract available.


High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study.

Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M, Østenstad B, Fluge Ø, Delabie J, Aarset H, Liestøl K, Holte H.

Br J Haematol. 2011 Mar;152(5):600-10. doi: 10.1111/j.1365-2141.2010.08519.x. Epub 2011 Jan 17. Review.


Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas.

Negaard HF, Svennevig K, Kolset SO, Iversen N, Lothe IM, Østenstad B, Sandset PM, Iversen PO.

Leuk Lymphoma. 2009 Jun;50(6):998-1004. doi: 10.1080/10428190902889270.


Hematopoietic engraftment of dimethyl sulfoxide-depleted autologous peripheral blood progenitor cells.

Akkök CA, Holte MR, Tangen JM, Ostenstad B, Bruserud O.

Transfusion. 2009 Feb;49(2):354-61. doi: 10.1111/j.1537-2995.2008.01949.x. Epub 2008 Oct 28.


Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors.

Negaard HF, Iversen N, Bowitz-Lothe IM, Sandset PM, Steinsvik B, Ostenstad B, Iversen PO.

Leukemia. 2009 Jan;23(1):162-9. doi: 10.1038/leu.2008.255. Epub 2008 Sep 18.


CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE.

PLoS One. 2008 Aug 26;3(8):e3062. doi: 10.1371/journal.pone.0003062.


Increased acquired activated protein C resistance in unselected patients with hematological malignancies.

Negaard HF, Iversen PO, Ostenstad B, Mowinckel MC, Sandset PM.

J Thromb Haemost. 2008 Sep;6(9):1482-7. doi: 10.1111/j.1538-7836.2008.03060.x. Epub 2008 Jun 28.


Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor.

Negaard HF, Iversen PO, Østenstad B, Iversen N, Holme PA, Sandset PM.

Thromb Haemost. 2008 Jun;99(6):1040-8. doi: 10.1160/TH07-09-0541.


Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group.

Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, Lehtinen T, Ostenstad B, Hansen M, Osterborg A, Lindén O, Sundström C; Nordic Lymphoma Group.

Leuk Lymphoma. 2008 Jan;49(1):102-12. doi: 10.1080/10428190701704647.


The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer.

Staalesen V, Knappskog S, Chrisanthar R, Nordgard SH, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Gram IT, Kristensen VN, Børresen-Dale AL, Lillehaug JR, Lønning PE.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6000-4.


Decreased lung cancer survival with hormone-replacement therapy: caused by a decreased tissue factor pathway inhibitor level?

Negaard HF, Eilertsen AL, Dahm A, Iversen PO, Østenstad B, Sandset PM.

J Clin Oncol. 2006 Jun 10;24(17):2683-4; author reply 2684. No abstract available.


Angiogenesis and hemostasis in hematological neoplasias.

Negaard H, Dahm A, Sandset PM, Iversen PO, Østenstad B.

Curr Drug Targets. 2005 Sep;6(6):683-99. Review.


Analysis of the humoral immune response to immunoselected phage-displayed peptides by a microarray-based method.

Cekaite L, Haug O, Myklebost O, Aldrin M, Østenstad B, Holden M, Frigessi A, Hovig E, Sioud M.

Proteomics. 2004 Sep;4(9):2572-82.


Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer.

Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremnes Y, Mjaaland I.

Acta Oncol. 2004;43(2):186-9.


HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review.

Carlsson J, Nordgren H, Sjöström J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H, Blomqvist C.

Br J Cancer. 2004 Jun 14;90(12):2344-8. Review.


Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer.

Wist EA, Sommer HH, Ostenstad B, Risberg T, Fjaestad K.

Acta Oncol. 2004;43(1):11-4.


Epidermal growth factor receptor inhibition induces trichomegaly.

Dueland S, Sauer T, Lund-Johansen F, Ostenstad B, Tveit KM.

Acta Oncol. 2003;42(4):345-6. No abstract available.


Tumour microvessel density as predictor of chemotherapy response in breast cancer patients.

Tynninen O, Sjöström J, von Boguslawski K, Bengtsson NO, Heikkilä R, Malmström P, Ostenstad B, Wist E, Valvere V, Saksela E, Paavonen T, Blomqvist C.

Br J Cancer. 2002 Jun 17;86(12):1905-8.


C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer.

Sjöström J, Collan J, von Boguslawski K, Franssila K, Bengtsson NO, Mjaaland I, Malmström P, Østenstad B, Wist E, Valvere V, Bergh J, Skiöld-Petterson D, Saksela E, Blomqvist C.

Eur J Cancer. 2002 Mar;38(4):535-42.


Timing of quality of life (QoL) assessments as a source of error in oncological trials.

Hakamies-Blomqvist L, Luoma ML, Sjöström J, Pluzanska A, Sjödin M, Mouridsen H, Østenstad B, Mjaaland I, Ottosson S, Bergh J, Malmström PO, Blomqvist C.

J Adv Nurs. 2001 Sep;35(5):709-16.


Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.

Hakamies-Blomqvist L, Luoma M, Sjöström J, Pluzanska A, Sjödin M, Mouridsen H, Ostenstad B, Mjaaland I, Ottosson-Lönn S, Bergh J, Malmström P, Blomqvist C.

Eur J Cancer. 2000 Jul;36(11):1411-7.


Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lönn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjövall M, Wist E, Valvere V, Anderson H, Bergh J.

Eur J Cancer. 1999 Aug;35(8):1194-201.


A boy with X-linked hyper-IgM syndrome and natural killer cell deficiency.

Ostenstad B, Giliani S, Mellbye OJ, Nilsen BR, Abrahamsen T.

Clin Exp Immunol. 1997 Feb;107(2):230-4.


Supplemental Content

Loading ...
Support Center